Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Walker BA et al. | Adenosine A3 receptor expression and function in eosinophils. | 1997 | Am. J. Respir. Cell Mol. Biol. | pmid:9160835 |
Dent G et al. | Protein kinase C inhibition enhances platelet-activating factor-induced eicosanoid production in human eosinophils. | 1998 | Am. J. Respir. Cell Mol. Biol. | pmid:9448055 |
Gomez J et al. | Characterization of receptors for platelet-activating factor in guinea pig lung membranes. | 1990 | Am. J. Respir. Cell Mol. Biol. | pmid:2167700 |
Nagase T et al. | Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor. Roles of thromboxanes and leukotrienes. | 1997 | Am. J. Respir. Crit. Care Med. | pmid:9372685 |
Larkin EK et al. | New risk factors for adult-onset incident asthma. A nested case-control study of host antioxidant defense. | 2015 | Am. J. Respir. Crit. Care Med. | pmid:25408961 |
Samapati R et al. | Lung endothelial Ca2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6. | 2012 | Am. J. Respir. Crit. Care Med. | pmid:22246702 |
Masclans JR et al. | Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans. | 1996 | Am. J. Respir. Crit. Care Med. | pmid:8756833 |
Maruoka S et al. | PAF-induced RANTES production by human airway smooth muscle cells requires both p38 MAP kinase and Erk. | 2000 | Am. J. Respir. Crit. Care Med. | pmid:10712344 |
Spence DP et al. | The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8173754 |
Fukuyama S et al. | Effect of eotaxin and platelet-activating factor on airway inflammation and hyperresponsiveness in guinea pigs in vivo. | 2000 | Am. J. Respir. Crit. Care Med. | pmid:10852755 |
Pretolani M et al. | Role of eosinophil activation in the bronchial reactivity of allergic guinea pigs. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8173756 |
Kafoury RM et al. | Induction of inflammatory mediators in human airway epithelial cells by lipid ozonation products. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:10588609 |
McBride DE et al. | Inflammatory effects of ozone in the upper airways of subjects with asthma. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8173759 |
Göggel R et al. | Platelet-activating factor-induced pulmonary edema is partly mediated by prostaglandin E(2), E-prostanoid 3-receptors, and potassium channels. | 2002 | Am. J. Respir. Crit. Care Med. | pmid:12204861 |
Thorne JR and Broadley KJ | Adenosine-induced bronchoconstriction in conscious hyperresponsive and sensitized guinea pigs. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8306036 |
Lou YP et al. | Platelet-activating factor induces goblet cell hyperplasia and mucin gene expression in airways. | 1998 | Am. J. Respir. Crit. Care Med. | pmid:9620929 |
Falk S et al. | Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:10556149 |
Nakos G et al. | Bronchoalveolar lavage alterations in pulmonary embolism. | 1998 | Am. J. Respir. Crit. Care Med. | pmid:9817700 |
Kuitert LM et al. | Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. | 1995 | Am. J. Respir. Crit. Care Med. | pmid:7735582 |
Mason GR et al. | The effect of inhalation of platelet-activating factor on the pulmonary clearance of 99mTc-DTPA aerosol. | 1995 | Am. J. Respir. Crit. Care Med. | pmid:7735622 |
Félez MA et al. | Inhaled platelet-activating factor worsens gas exchange in mild asthma. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8049817 |
Gómez FP et al. | The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. | 1998 | Am. J. Respir. Crit. Care Med. | pmid:9603138 |
Berger A et al. | Dioleylphosphatidylglycerol inhibits the expression of type II phospholipase A2 in macrophages. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:9927381 |
Roca J et al. | Salbutamol inhibits pulmonary effects of platelet activating factor in man. | 1995 | Am. J. Respir. Crit. Care Med. | pmid:7767515 |
Ohar JA et al. | Chronic platelet-activating factor induces a decrease in pulmonary vascular compliance, hydroxyproline, and loss of vascular matrix. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8004322 |
Shin MH et al. | Nasal allergen challenge generates 1-0-hexadecyl-2-lyso-sn-glycero-3-phosphocholine. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8118633 |
Chen CR et al. | Platelet-activating factor potentiates protamine-induced lung edema. Role of eicosanoids. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8111595 |
Lekka ME et al. | The impact of intravenous fat emulsion administration in acute lung injury. | 2004 | Am. J. Respir. Crit. Care Med. | pmid:14656749 |
Satoh N et al. | Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:10051281 |
Henig NR et al. | Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. | 2000 | Am. J. Respir. Crit. Care Med. | pmid:10934081 |
Sulakvelidze I and McDonald DM | Anti-edema action of formoterol in rat trachea does not depend on capsaicin-sensitive sensory nerves. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:7509246 |
Nagase T et al. | Airway hyperresponsiveness in transgenic mice overexpressing platelet activating factor receptor is mediated by an atropine-sensitive pathway. | 2002 | Am. J. Respir. Crit. Care Med. | pmid:11790655 |
O'Connor BJ et al. | Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:8025768 |
Evans DJ et al. | Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. | 1997 | Am. J. Respir. Crit. Care Med. | pmid:9230719 |
DÃaz O et al. | Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation. | 1997 | Am. J. Respir. Crit. Care Med. | pmid:9230720 |
Triggiani M et al. | Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. | 1997 | Am. J. Respir. Crit. Care Med. | pmid:9230731 |
Hozawa S et al. | Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. | 1995 | Am. J. Respir. Crit. Care Med. | pmid:7551370 |
Imai Y et al. | Inflammatory chemical mediators during conventional ventilation and during high frequency oscillatory ventilation. | 1994 | Am. J. Respir. Crit. Care Med. | pmid:7952613 |
Yan ZY et al. | Platelet activating factor-induced changes in gastric motility and vascular resistance. | 1992 | Am. J. Surg. | pmid:1346361 |
Soybel DI et al. | Effects of platelet-activating factor on canine gastric mucosal blood flow and permeability to luminal acid. | 1988 | Am. J. Surg. | pmid:3341532 |
Ono S et al. | A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. | 1996 | Am. J. Surg. | pmid:8604832 |
Diez-Fraile A et al. | Effect of proinflammatory mediators and glucocorticoids on L-selectin expression in peripheral blood neutrophils from dairy cows in various stages of lactation. | 2004 | Am. J. Vet. Res. | pmid:15524330 |
Kingston JK et al. | Measurement of the activation of equine platelets by use of fluorescent-labeled annexin V, anti-human fibrinogen antibody, and anti-human thrombospondin antibody. | 2002 | Am. J. Vet. Res. | pmid:11939312 |
Menzies-Gow NJ et al. | Roles of thromboxane A2 and 5-hydroxytryptamine in endotoxin-induced digital vasoconstriction in horses. | 2008 | Am. J. Vet. Res. | pmid:18241016 |
Wilson DV et al. | Histologic and ultrastructural changes after large-colon torsion, with and without use of a specific platelet-activating factor antagonist (WEB 2086), in ponies. | 1994 | Am. J. Vet. Res. | pmid:8067617 |
Wilson DV et al. | Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086. | 1993 | Am. J. Vet. Res. | pmid:8430938 |
McClenahan DJ et al. | In vitro evaluation of the role of platelet-activating factor and interleukin-8 in Mannheimia haemolytica-induced bovine pulmonary endothelial cell injury. | 2002 | Am. J. Vet. Res. | pmid:11911574 |
Burgos RA et al. | Determination of specific receptor sites for platelet activating factor in bovine neutrophils. | 2004 | Am. J. Vet. Res. | pmid:15141884 |
Walz PH et al. | Platelet function and association of bovine viral diarrhea virus with platelets of persistently infected cattle. | 2005 | Am. J. Vet. Res. | pmid:16273905 |
LeBlanc CJ et al. | Effects of dietary supplementation with fish oil on in vivo production of inflammatory mediators in clinically normal dogs. | 2008 | Am. J. Vet. Res. | pmid:18380580 |